Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding
Pharmacy Times
JULY 18, 2025
Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. 1 For 503A pharmacy compounders, there are limited but clearly proscribed circumstances that GLP-1 compounding may continue.
Let's personalize your content